Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(13):975-976; doi:10.1093/jnci/93.13.975
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Miller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 13, 975-976, July 4, 2001
© 2001 Oxford University Press

NEWS

Biomarkers, Animal Models Key in Progress of Chemoprevention

Mike Miller

Tamoxifen and celecoxib, used, respectively, for prevention of some types of breast and colon cancers, are the only drugs approved by the U.S. Food and Drug Administration to help reduce the risk of cancer.

Although chemoprevention holds great promise, challenges ahead include identifying refined clinical markers, discovering better predictive mouse models, and developing genomic and proteomic analyses that can identify precursor lesions.

Biomarkers are one key to developing new prevention drugs and getting them to market in a more timely manner, . . . [Full Text of this Article]

Different Mechanisms of Action

Animal Models

Estrogen Receptors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?